Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin in Parkinson Disease Psychosis
NCT05357612Phase 4Recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jan 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pimavanserin in Parkinson's disease psychosis (PDP), sponsored by Vanderbilt University Medical Center. Started Jan 2023; status: recruiting.
02
Drugs
pimavanserin
03
Conditions
Parkinson's disease psychosis (PDP)
Beyond the preview
Go deeper on NCT05357612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05357612.